University of Maryland School of Medicine, Division of Endocrinology, Diabetes and Nutrition, Baltimore, Maryland.
University of Maryland Medical Center, Department of Internal Medicine, Baltimore, Maryland.
Endocr Pract. 2021 Aug;27(8):842-849. doi: 10.1016/j.eprac.2021.05.011. Epub 2021 Jun 6.
Diabetes is an independent risk factor for severe SARS-CoV-2 infections. This study aims to elucidate the risk factors predictive of more severe outcomes in patients with diabetes by comparing the clinical characteristics of those requiring inpatient admissions with those who remain outpatient.
A retrospective review identified 832 patients-631 inpatients and 201 outpatients-with diabetes and a positive SARS-CoV-2 test result between March 1 and June 15, 2020. Comparisons between the outpatient and inpatient cohorts were conducted to identify risk factors associated with severity of disease determined by admission rate and mortality. Previous dipeptidyl peptidase 4 inhibitor use and disease outcomes were analyzed.
Risk factors for increased admission included older age (odds ratio [OR], 1.04 [95% CI, 1.01-1.06]; P = .003), the presence of chronic kidney disease (OR, 2.32 [1.26-4.28]; P = .007), and a higher hemoglobin A1c at the time of admission (OR, 1.25 [1.12-1.39]; P < .001). Lower admission rates were seen in those with commercial insurance. Increased mortality was seen in individuals with older age (OR, 1.09 [1.07-1.11]; P < .001), higher body mass index number (OR, 1.04 [1.01-1.07]; P = .003), and higher hemoglobin A1c value at the time of diagnosis of COVID-19 (OR, 1.12 [1.01-1.24]; P = .028) and patients requiring hospitalization. Lower mortality was seen in those with hyperlipidemia. Dipeptidyl peptidase 4 inhibitor use prior to COVID-19 infection was not associated with a decreased hospitalization rate.
This retrospective review offers the first analysis of outpatient predictors for admission rate and mortality of COVID-19 in patients with diabetes.
糖尿病是严重 SARS-CoV-2 感染的独立危险因素。本研究旨在通过比较需要住院和门诊治疗的患者的临床特征,阐明预测糖尿病患者更严重结局的危险因素。
回顾性分析了 2020 年 3 月 1 日至 6 月 15 日期间患有糖尿病和 SARS-CoV-2 检测结果阳性的 832 例患者,其中 631 例为住院患者,201 例为门诊患者。比较门诊和住院两组患者的临床特征,以确定与住院率和死亡率相关的疾病严重程度的危险因素。分析了既往二肽基肽酶 4 抑制剂的使用情况和疾病结局。
住院率增加的危险因素包括年龄较大(优势比[OR],1.04[95%置信区间,1.01-1.06];P=0.003)、合并慢性肾脏病(OR,2.32[1.26-4.28];P=0.007)和入院时血红蛋白 A1c 较高(OR,1.25[1.12-1.39];P<0.001)。有商业保险的患者住院率较低。年龄较大(OR,1.09[1.07-1.11];P<0.001)、体重指数较高(OR,1.04[1.01-1.07];P=0.003)和 COVID-19 诊断时血红蛋白 A1c 值较高(OR,1.12[1.01-1.24];P=0.028)以及需要住院治疗的患者死亡率较高。患有高脂血症的患者死亡率较低。COVID-19 感染前使用二肽基肽酶 4 抑制剂与住院率降低无关。
本回顾性分析首次分析了门诊患者预测糖尿病 COVID-19 住院率和死亡率的因素。